Suppr超能文献

角膜环段联合虹膜固定型有晶状体眼人工晶状体治疗圆锥角膜的屈光和视觉改善。

Combined intracorneal ring segments and iris-fixated phakic intraocular lens for keratoconus refractive and visual improvement.

出版信息

J Refract Surg. 2014 May;30(5):336-41. doi: 10.3928/1081597X-20140319-01. Epub 2014 Mar 26.

Abstract

PURPOSE

To evaluate the efficacy and safety of keratoconus refractive and visual improvement by combined intracorneal ring segments (ICRS; Intacs/Intacs SK, Addition Technology Inc., Des Moines, IL) and phakic intraocular lens (PIOL; Artisan/Artiflex Toric IOL, Ophtec BV, Groningen, Holland) implantation.

METHODS

This study comprised patients who had ICRS implantation followed by PIOL implantation 6 or more months later for the correction of keratoconus. Over a 12-month follow-up after PIOL implantation, the main outcome measures were uncorrected and corrected distance visual acuity (UDVA and CDVA), spherical equivalent refraction, and central endothelial cell density. Efficacy and safety indexes were calculated.

RESULTS

The study included 21 eyes of 16 patients. The mean UDVA 12 months after ICRS and PIOL implantation increased from 2.0 ± 0 to 0.25 ± 0.22 logMAR (Snellen 20/2000 to 20/35) (P < .001). The mean CDVA increased from 0.31 ± 0.13 to 0.13 ± 0.13 log-MAR (Snellen 20/40 to 20/25) (P = .039). Predictability of refractive results was good, with spherical equivalent refraction within ±0.50 diopter of the attempted correction in 13 eyes (61.9%) and within ±1.00 diopter in 19 eyes (90.5%). Mean central endothelial cell density decreased from 2,513 ± 245 cells/mm(2) preoperatively to 2,312 ± 263 cells/mm(2) (P = .402). The efficacy index was 1.06 and the safety index was 1.40.

CONCLUSIONS

Keratoconus visual and refractive improvement by the sequential implantation of Intacs ICRS and Artisan/Artiflex Toric IOL is a safe and predictable procedure.

摘要

目的

评估角膜环段(ICRS;Intacs/Intacs SK,Addition Technology Inc.,Des Moines,IL)联合有晶状体眼人工晶状体(PIOL;Artisan/Artiflex Toric IOL,Ophtec BV,Groningen,Holland)植入对圆锥角膜屈光和视力改善的疗效和安全性。

方法

本研究包括接受 ICRS 植入术的患者,6 个月后再行 PIOL 植入术矫正圆锥角膜。PIOL 植入术后 12 个月的主要观察指标为未矫正和矫正远距视力(UDVA 和 CDVA)、等效球镜屈光度和中央角膜内皮细胞密度。计算疗效和安全性指标。

结果

本研究共纳入 16 例 21 只眼。ICRS 和 PIOL 植入术后 12 个月时,UDVA 从 2.0±0 提高到 0.25±0.22 logMAR(Snellen 20/2000 至 20/35)(P<0.001)。CDVA 从 0.31±0.13 提高到 0.13±0.13 logMAR(Snellen 20/40 至 20/25)(P=0.039)。屈光结果的预测性良好,13 只眼(61.9%)的等效球镜屈光度在尝试矫正的±0.50 屈光度范围内,19 只眼(90.5%)在±1.00 屈光度范围内。中央角膜内皮细胞密度从术前的 2513±245 个/mm² 降至术后的 2312±263 个/mm²(P=0.402)。疗效指数为 1.06,安全性指数为 1.40。

结论

角膜环段(ICRS)联合有晶状体眼人工晶状体(PIOL)序贯植入术治疗圆锥角膜,可改善视力和屈光,是一种安全、可预测的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验